Regulatory approval

Published by the Health Service Executive. Withdrawn

Treatment of patients with RAS wild type metastatic colorectal cancer.

This is written in the approval document.

Reimbursement

N/A

Citation

Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-06-03	Health Service Executive	Indication approved for reimbursement.